Literature DB >> 31114988

MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1.

X-L Zhang1, B-L Sun, S-X Tian, L Li, Y-C Zhao, P-P Shi.   

Abstract

OBJECTIVE: To explore the role of micro ribonucleic acid-132 (miR-132) in cisplatin (DDP) resistance and metastasis of ovarian cancer and its related mechanisms.
MATERIALS AND METHODS: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting were applied to detect the expression levels of miR-132 and B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) in maternal SKOV3 cells and cisplatin-resistant SKOV3/DDP cells. SKOV3/DDP cells were transfected with miR-132 mimic and miR-132 mimic negative control (NC). QRT-PCR and Western blotting were used to detect the expression changes in Bmi-1, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was adopted to detect the sensitivity of cells to DDP after transfection with miR-132 mimic. The effect of transfection on the apoptosis was detected via flow cytometry, and that on cell invasion and migration abilities were examined using wound healing assay and transwell assay. Bmi-1 wild-type (wt) and mutant-type (mut) luciferase reporter plasmids were co-transfected with miRNA-132 mimic or miRNA-132 NC, and luciferase activity was analyzed by dual-luciferase reporter system.
RESULTS: QRT-PCR and Western blotting results manifested that the miR-132 expression level in SKOV3/DDP cells was significantly lower than that in SKOV3 cells, while the expression level of Bmi-1 in SKOV3/DDP cells was significantly higher than that in SKOV3 cells. The overexpression of miR-132 could reduce the expression level of Bmi-1 in SKOV3/DDP cells, increase the sensitivity of SKOV3/DDP cells to DDP, and inhibit cell invasion and metastasis. Data detected by the luciferase activity revealed that miR-132 could bind to the three prime untranslated region (3'-UTR) of the Bmi-1 gene and negatively regulate the protein expression.
CONCLUSIONS: MiR-132 may regulate ovarian cancer's sensitivity to DDP and inhibit its invasion and metastasis by targeted regulation on Bmi-1.

Entities:  

Year:  2019        PMID: 31114988     DOI: 10.26355/eurrev_201905_17787

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

Review 1.  Regulators at Every Step-How microRNAs Drive Tumor Cell Invasiveness and Metastasis.

Authors:  Tomasz M Grzywa; Klaudia Klicka; Paweł K Włodarski
Journal:  Cancers (Basel)       Date:  2020-12-10       Impact factor: 6.639

2.  Hsa-miR-105-1 Regulates Cisplatin-Resistance in Ovarian Carcinoma Cells by Targeting ANXA9.

Authors:  Xinxin Kou; Hui Ding; Lei Li; Hongtu Chao
Journal:  Anal Cell Pathol (Amst)       Date:  2021-02-24       Impact factor: 2.916

Review 3.  MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells.

Authors:  Meysam Moghbeli
Journal:  J Ovarian Res       Date:  2021-09-30       Impact factor: 4.234

Review 4.  The Crucial Roles of Bmi-1 in Cancer: Implications in Pathogenesis, Metastasis, Drug Resistance, and Targeted Therapies.

Authors:  Jie Xu; Lin Li; Pengfei Shi; Hongjuan Cui; Liqun Yang
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

Review 5.  Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.

Authors:  Amoolya Kandettu; Divya Adiga; Vasudha Devi; Padmanaban S Suresh; Sanjiban Chakrabarty; Raghu Radhakrishnan; Shama Prasada Kabekkodu
Journal:  Genes Dis       Date:  2022-03-01

6.  MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1.

Authors:  Liqiang Chen; Qingli Zhu; Lingwei Lu; Yanshan Liu
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

7.  miR‑132 is upregulated in polycystic ovarian syndrome and inhibits granulosa cells viability by targeting Foxa1.

Authors:  Xiangrong Cui; Xuan Jing; Junfen Liu; Xingyu Bi; Xueqing Wu
Journal:  Mol Med Rep       Date:  2020-10-14       Impact factor: 2.952

8.  BMI-1 Expression Heterogeneity in Endometriosis-Related and Non-Endometriotic Ovarian Carcinoma.

Authors:  Ludmila Lozneanu; Raluca Anca Balan; Ioana Păvăleanu; Simona Eliza Giuşcă; Irina-Draga Căruntu; Cornelia Amalinei
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.